Literature DB >> 22832318

Optimization of tricyclic Nec-3 necroptosis inhibitors for in vitro liver microsomal stability.

Sungwoon Choi1, Heather Keys, Richard J Staples, Junying Yuan, Alexei Degterev, Gregory D Cuny.   

Abstract

Necroptosis is a regulated caspase-independent cell death pathway with morphological features resembling passive non-regulated necrosis. Several diverse structure classes of necroptosis inhibitors have been reported to date, including a series of 3,3a,4,5-tetrahydro-2H-benz[g]indazoles (referred to as the Nec-3 series) displaying potent activity in cellular assays. However, evaluation of the tricyclic necroptosis inhibitor's stability in mouse liver microsomes indicated that they were rapidly degraded. A structure-activity relationship (SAR) study of this compound series revealed that increased liver microsomal stability could be accomplished by modification of the pendent phenyl ring and by introduction of a hydrophilic substituent (i.e., α-hydroxyl) to the acetamide at the 2-position of the tricyclic ring without significantly compromising necroptosis inhibitory activity. Further increases in microsomal stability could be achieved by utilizing the 5,5-dioxo-3-phenyl-2,3,3a,4-tetrahydro-[1]benzothiopyrano[4,3-c]pyrazoles. However, in this case necroptosis inhibitory activity was not maintained. Overall, these results provide a strategy for generating potent and metabolically stable tricyclic necrostatin analogs (e.g., 33, LDN-193191) potentially suitable for in vivo studies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22832318      PMCID: PMC3434878          DOI: 10.1016/j.bmcl.2012.06.098

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  24 in total

Review 1.  Mechanisms, challenges and opportunities in stroke.

Authors:  Eng H Lo; Turgay Dalkara; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2003-05       Impact factor: 34.870

Review 2.  New therapeutic strategy for Parkinson's and Alzheimer's disease.

Authors:  E Esposito; S Cuzzocrea
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

3.  Structure-activity relationship study of tricyclic necroptosis inhibitors.

Authors:  Prakash G Jagtap; Alexei Degterev; Sungwoon Choi; Heather Keys; Junying Yuan; Gregory D Cuny
Journal:  J Med Chem       Date:  2007-03-16       Impact factor: 7.446

Review 4.  Expansion and evolution of cell death programmes.

Authors:  Alexei Degterev; Junying Yuan
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

Review 5.  Molecular mechanisms of necroptosis: an ordered cellular explosion.

Authors:  Peter Vandenabeele; Lorenzo Galluzzi; Tom Vanden Berghe; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2010-09-08       Impact factor: 94.444

6.  Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease.

Authors:  S Zhu; Y Zhang; G Bai; H Li
Journal:  Cell Death Dis       Date:  2011       Impact factor: 8.469

7.  Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors.

Authors:  Xin Teng; Heather Keys; Arumugasamy Jeevanandam; John A Porco; Alexei Degterev; Junying Yuan; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2007-10-17       Impact factor: 2.823

8.  Necrostatin: a potentially novel cardioprotective agent?

Authors:  Christopher C T Smith; Sean M Davidson; Shiang Y Lim; James C Simpkin; John S Hothersall; Derek M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  2007-07-31       Impact factor: 3.727

9.  Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice.

Authors:  Zerong You; Sean I Savitz; Jinsheng Yang; Alexei Degterev; Junying Yuan; Gregory D Cuny; Michael A Moskowitz; Michael J Whalen
Journal:  J Cereb Blood Flow Metab       Date:  2008-05-21       Impact factor: 6.200

10.  Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury.

Authors:  James D McCully; Hidetaka Wakiyama; Yng-Ju Hsieh; Mara Jones; Sidney Levitsky
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-01-08       Impact factor: 4.733

View more
  6 in total

Review 1.  Cell death controlling complexes and their potential therapeutic role.

Authors:  Alexey V Zamaraev; Gelina S Kopeina; Boris Zhivotovsky; Inna N Lavrik
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

2.  Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.

Authors:  Malek Najjar; Chalada Suebsuwong; Soumya S Ray; Roshan J Thapa; Jenny L Maki; Shoko Nogusa; Saumil Shah; Danish Saleh; Peter J Gough; John Bertin; Junying Yuan; Siddharth Balachandran; Gregory D Cuny; Alexei Degterev
Journal:  Cell Rep       Date:  2015-03-24       Impact factor: 9.423

Review 3.  Generation of small molecules to interfere with regulated necrosis.

Authors:  Alexei Degterev; Andreas Linkermann
Journal:  Cell Mol Life Sci       Date:  2016-04-05       Impact factor: 9.261

4.  The effect and underlying mechanism of Timosaponin B-II on RGC-5 necroptosis induced by hydrogen peroxide.

Authors:  San-Hong Jiang; Lei Shang; Li-Xiang Xue; Wei Ding; Shuang Chen; Ruo-Fei Ma; Ju-Fang Huang; Kun Xiong
Journal:  BMC Complement Altern Med       Date:  2014-12-02       Impact factor: 3.659

5.  Design and Synthesis of New 6-Nitro and 6-Amino-3,3a,4,5-Tetrahydro-2H-Benzo[g]indazole Derivatives: Antiproliferative and Antibacterial Activity.

Authors:  Viviana Cuartas; María Del Pilar Crespo; Eva-María Priego; Leentje Persoons; Dirk Daelemans; María-José Camarasa; Braulio Insuasty; María-Jesús Pérez-Pérez
Journal:  Molecules       Date:  2019-11-21       Impact factor: 4.411

Review 6.  Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy.

Authors:  Mao-Bin Meng; Huan-Huan Wang; Yao-Li Cui; Zhi-Qiang Wu; Yang-Yang Shi; Nicholas G Zaorsky; Lei Deng; Zhi-Yong Yuan; You Lu; Ping Wang
Journal:  Oncotarget       Date:  2016-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.